ArticleFrontiers in microbiology2015
New strategic insights into managing fungal biofilms.
Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Review
- Discovery and development of novel substituted monohydrazides as potent antifungal agents.RSC medicinal chemistry · 2023Article
- Characterization of oral candidiasis according to antiretroviral treatment status, immunological and virological profiles among HIV infected patients in two health facilities in Yaoundé-Cameroon: a cross-sectional and analytical study.The Pan African medical journal · 2023Article
- Two New Compounds Containing Pyridinone or Triazine Heterocycles Have Antifungal Properties againstAntibiotics (Basel, Switzerland) · 2022Article
- Antifungal Activity of the Extract of a Macroalgae,Plants (Basel, Switzerland) · 2021Article
- Comprehensive transcriptomic and proteomic analyses identify intracellular targets for myriocin to induce Fusarium oxysporum f. sp. niveum cell death.Microbial cell factories · 2021Article
- Phenomic profiling of a novel sibling species within the Scedosporium complex in Thailand.BMC microbiology · 2021Article
- Multi-pathogen infections and Alzheimer's disease.Microbial cell factories · 2021Review
- Potential of Exopolysaccharide fromMarine drugs · 2021Article
- Mechanistic Understanding ofFrontiers in microbiology · 2021Review
- Article
- Article
- Methidathion Poisoning.Korean journal of critical care medicine · 2017Article
- Biofilm Formation byFrontiers in microbiology · 2017Article
- A Multispecies Fungal Biofilm Approach to Enhance the Celluloyltic Efficiency of Membrane Reactors for Consolidated Bioprocessing of Plant Biomass.Frontiers in microbiology · 2017Article
- Fungal Biofilms: Targets for the Development of Novel Strategies in Plant Disease Management.Frontiers in microbiology · 2017Article
- Sphingolipids as targets for treatment of fungal infections.Future medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation, or other chronic diseases. Such opportunistic infections result from a complex relationship between fungi and host, and can range from self-limiting to chronic or life-threatening infections. Modern medicine, characterized by a wide use of biomedical devices, offers new niches for fungi to colonize and form biofilm communities. The capability of fungi to form biofilms is well documented and associated with increased drug tolerance and resistance. In addition, biofilm formation facilitates persistence in the host promoting a persistent inflammatory condition. With a limited availability of antifungals within our arsenal, new therapeutic approaches able to address both host and pathogenic factors that promote fungal disease progression, i.e., chronic inflammation and biofilm formation, could represent an advantage in the clinical setting. In this paper we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of their already known anti-inflammatory activity and as candidate dual action therapeutics to treat opportunistic fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.